We are pleased to announce that Egil Mølsted Madsen will assume the role of CFO at Karo starting on 3 October 2024. Egil, a Danish national, brings a wealth of experience from his previous roles as CFO in the healthcare sector at companies such as Atos Medical, SSI Diagnostica and Agilent/Dako, as well as valuable...
Today, on 15 April 2024, Karo Group* is publishing its 2023 Sustainability Report on the company’s website, www.karohealthcare.com. For further information, please contact: Christoffer Lorenzen, CEO, +46 735 017 620, christoffer.lorenzen@karo.com Lisa Westerdahl, Chief People & Sustainability Officer, +46 733 297 004, lisa.westerdahl@karo.com About Karo Group Karo Group consists of Karo Intressenter Holding AB and...
Karo Healthcare AB (‘Karo’) announces the acquisition of the rights to the OTC brand Proctosedyl from Bayer. The transaction transfers global dossier ownership to the OTC pharmaceutical Proctosedyl, and exclusive license to the Proctosedyl trademark in Italy, from Bayer to Karo. This acquisition amplifies Karo’s presence in Italy while aligning with Karo’s M&A strategy of...
